Document is current
Any future updates will be listed below
-
Authors
Kumar, Vinod
Yochum, Zachary A.
Devadassan, Princey
Huang, Eric H.-B.
Miller, Ethan
Baruwal, Roja
Rumde, Purva H.
GaitherDavis, Autumn L.
Stabile, Laura P.
Burns, Timothy F. https://orcid.org/0000-0002-8685-3762
-
Funding
Funding for this research was provided by:
American Cancer Society (RSG TBG – 132939)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI R01 CA244270-01A1, P50CA090440, 1F30CA213765 01)
V Foundation for Cancer Research
American Lung Association (LCD-257864)
Doris Duke Charitable Foundation (2015097)
Sidney Kimmel Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
The We Wish Foundation
Howard Hughes Medical Institute (Medical Fellowship)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMST32GM008421-22)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 21 November 2023
Revised: 15 February 2024
Accepted: 19 February 2024
First Online: 1 March 2024
Competing interests
: TFB declares potential competing financial interests related to the publication of this study. TFB has served as a compensated consultant for a DSMB: Advarra, Inc (Lantern Pharma); Scientific Advisory Board member: (no stock) Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals Inc, Blueprint Medicines Corporation (BPMC), Emd Serono Inc, Mirati Therapeutics, Inc., Amgen, AstraZeneca, and Takeda Pharmaceuticals U.S.A., Inc, and received institutional research funds from Novartis (all to institution).
